Prevalence of fracture risk among middle-aged and elderly population of Gujarat, India: an observational study

Bhoomika G. Brahmbhatt, Megha S. Sheth


Background: This study was conducted to estimate the prevalence of fracture risk among middle-aged and elderly population of Gujarat and to find out the prevalence of the clinical risk factors (CRF) and its significance with risk of fracture. To compare the risk of fracture among men and women.

Methods: An observational study included 500 participants both men and women, in age group of 40-80 years. Participants were assessed with the fracture risk assessment tool (FRAX) without BMD to evaluate the 10-year probability of risk of Major osteoporotic fracture (MOF) and Hip fracture (HF). India-specific age-dependent thresholds were used to categorize the participants into safety zone and treatment zone followed by statistical analysis. Level of significance was kept at 5%.

Results: Total 500 participants, 56.8% males and 43.2% females with mean age 56.3±9.7 years. As per the estimated prevalence, 22% participants were in treatment zone and 78% were in safety zone for HF risk and for major osteoporotic fracture risk, 24% participants were in treatment zone and 76% were in safety zone. In 18.6% participants the hip fracture risk was ≥3% and in 2% participants the major osteoporotic fracture risk was ≥20%. Women had more fracture risk compare to men, for HF [t (464.6)=-3.04, p=0.002] and for MOF [t (441.3)=-5.13, p<0.001]. Significant difference in fracture risk was found with presence of CRF except with smoking and alcohol use.

Conclusions: FRAX can be used to identify the 10-year probability of fracture risk. The prevalence showed fewer participants in treatment zone and more in safety zone. Women had higher fracture probabilities than men.


Clinical risk factors, Fracture risk, FRAX, Osteoporosis, Gujarat, Prevalence

Full Text:



International osteoporosis foundation (IOF) Guidelines. Available from:

Kristine E. Epidemiology of Fracture Risk with Advancing Age. J Gerontol. 2013;68(10):1236-42.

National Institute for Health and Clinical Excellence. Quality and outcomes framework (QOF) indicator guidance. Indicator area: Osteoporosis: secondary prevention of fragility fractures. 2011. Available from:

Asia-Pacific Regional Audit-2009. Available from:

Mithal A, Kaur P. Osteoporosis in Asia: a call to action. Curr Osteoporos Rep. 2012;10(4):245-7.

Malhotra N, Mithal A. Osteoporosis in Indians. Indian J Med Res. 2008;127(3):263-8.

Dhanwal D, Siwach R, Dixit V, Mithal A, Jameson, Cooper C. Incidence of hip fracture in Rohtak district, North India. Arch Osteoporos. 2013;8:135-9.

Kanis J, Johnell O, Oden A, Johansson H, McCloskey E. FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385-97.

Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, et al. Assessment of fracture risk. Osteoporosis International 2005; 16: 581-589.

Silverman S, Calderon A. The utility and limitations of FRAX: A US perspective. Curr Osteoporos Rep. 2010; 8(4):192-7

Kanis J. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002;359:1929-36.

Kanis JA, Oden A, Johansson H, Borgström F, Ström O, McCloskey E. FRAX® and its applications to clinical practice. Bone. 2009;44(5):734-43.

Kanis J, Harvey N, Cooper C, Johansson H, Oden A, McCloskey E. Advisory Board of the National Osteoporosis Guideline Group. A systematic review of intervention thresholds based on FRAX: A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos. 2016;11(1):25.

National Osteoporosis Foundation (NOF)/ International Society for Clinical Densitometry (ISCD) FRAX Implementation Guide (2009):,

Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N. National Osteoporosis Guideline Group (NOGG). UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017;12(1):43.

Kanis J. Commentary on guidelines on postmenopausal osteoporosis- Indian Menopause Society. J Midlife Health. 2013;4(2):129-31.

Body mass index, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention (CDC), USA. Available from: assessing/bmi/index.html.

Vaishya R, Vijay V, Agarwal A, Maheshwari P. Assessment of osteoporotic fracture risk in urban Indian population using quantitative ultrasonography and FRAX tool. Indian J Med Res. 2017;146:S51-6.

Curtis E, Moon R, Harvey N, Cooper C. The impact of fragility fracture and approaches to osteoporosis risk assessment worldwide. Int J Orthop Trauma Nurs. 2017;8(26):7-17.

Choi S, Kwon S, Jung J, Kim, H, Kim S, Kim S, et al. Prevalence and fracture risk of osteoporosis in patients with rheumatoid arthritis: a multicenter comparative study of the FRAX and WHO criteria. J Clin Med. 2018;7(12):507.

Hillier T, Cauley J, Rizzo J, Pedula K, Ensrud K, Bauer D, et al. WHO absolute fracture risk models (FRAX): Do clinical risk factors improve fracture prediction in older women without osteoporosis? J Bone Min Res.2011;26(8):1774-82.

Zerbini C, Szejnfeld V, Abergaria B, McCloskey E, Johansson H, Kanis J. Incidence of hip fracture in Brazil and the development of a FRAX model. Arch Osteoporos. 2015;10:28.

Perry S, Downey P. Fracture Risk and Prevention: a multidimensional approach. Phys Therap. 2011;92(1):164-78.

Simpkins R, Downs T, Lane M. FRAX prediction with and without bone mineral density testing. Fed Pract. 2017;34(5):40-3.